Wells Fargo & Company Has Lowered Expectations for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price
Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its price objective decreased by Wells Fargo & Company from $50.00 to $45.00 in a report published on Wednesday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biotechnology company’s stock. A number of other equities analysts have also recently weighed in on ARCT. Canaccord […]
Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its price objective decreased by Wells Fargo & Company from $50.00 to $45.00 in a report published on Wednesday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biotechnology company’s stock. A number of other equities analysts have also recently weighed in on ARCT. Canaccord […]
